

Time to move forward: Challenges and Research Opportunities for Lung Cancer Screening and Early Detection in Europe

23 - 24 June 2022

Lisbon, Portugal

Thursday, 23 June 2022

08.30 – 08.45 Registration

08.45 – 09.00 Introduction – Jan van Meerbeeck, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any further progress?

09.00 – 09.20 *Two years after NELSON: Are there any further data on subgroup analyses or secondary endpoints?* – Harry De Koning, NL

09.20 – 09.40 *European agenda on lung cancer screening* – Brian Ward, BE

09.40 – 10.00 Keynote lecture – TBC

10.00 – 10.15 Discussion

10.15 – 10.45 *Coffee break*

10.45 – 12.45 Break-out session (whole group): What is currently ongoing in Europe?

- An update on current initiatives in different European countries
Chair: Jan van Meerbeeck
- Reflections from different European Countries

12.45 – 13.30 *Lunch break*

Session 2: Hurdles and barriers in implementation

13.30 – 13.50 *Is lung cancer screening cost-effective?* – TBC

13.50 – 14.10 *Psychological impact of lung cancer screening* – Georgia Hardavella, GR

14.10 – 14.30 *The voice of the participant* – Janette Rawlinson, UK

14.30 – 15.00 Discussion

15.00 – 16.30 Break out session 2: Challenges for implementation

- **Group 1:** Targeting the hard to reach
- **Group 2:** How will smoking cessation be integrated into your lung cancer screening program?

16.30 – 17.00 *Coffee break*

Session 3: The world does not stand still: evolution in diagnosis and treatment

- 17.00 – 17.20 *Is ultra-low-dose ready for practice?* – Mario Silva, IT
- 17.20 – 17.40 *Research opportunities in nodule handling: robotic surgery and beyond* – Witold Rzyman, PL
- 17.40 – 18.00 *Artificial Intelligence in lung cancer screening* – Colin Jacobs, NL
- 18.00 – 18.30 Discussion
- 19.30 *Dinner*

Friday, 24 June 2022

Session 4: Early detection biomarkers: ready for implementation in screening?

- 09.00 – 09.20 *Genomic screening: myths, promises and achievements* – Joanna Chorostowska, PL
- 09.20 – 09.40 *Biomarker performance and pathways to clinical utility* – Luis M. Montuenga, ES
- 09.40 – 10.00 *Reimaging diagnostic test development - harnessing the power of combination biomarkers* – Marc Van Der Schee, NL
- 10.00 – 10.30 Discussion
- 10.30 – 11.00 *Coffee break*

11.00 – 11.40 Report from break out session II

- Group 1 + discussion 20'
- Group 2 + discussion 20'

Session 5: Taking research forward in the EU

- 11.40 – 12.00 *What is the optimal design for trials incorporating biomarkers and CT-scan screening?*
– Hilary Robbins, FR
- 12.00-12.20 ERS Task forces on lung cancer screening – David Baldwin, UK
- 12.20-12.40 Projects submitted to the EU calls and ERS clinical research collaborations – Torsten Blum
- 12.40 – 13.00 Remarks, wrap up and action points
- 13.00 – 14.00 Lunch